Amazon to Expand Drone Delivery to 500 U.S. Locations 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Alibaba Shares Fall as AI Spending Hits Profit 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
REPAY Stock Rises After Visa Platform Connect Collaboration 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., May 03, 2018 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report first quarter 2018 financial and operating results after the U.S. financial markets close on Tuesday, May 8, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call and Webcast
Analysts and investors are invited to participate in the conference call by dialing 844-494-0193 (domestic) or 508-637-5584 (international) using the conference ID 1678364.
The webcast may be accessed live on the Investor Relations section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of two of the most prevalent forms of heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten is advancing into a pivotal Phase 3 clinical trial, known as EXPLORER-HCM in patients with symptomatic, obstructive HCM. MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase cardiac output in DCM patients by increasing the overall extent of the heart’s contraction cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
Contacts:
Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
[email protected]
Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
[email protected]
